EUVIMEDEUVIMED entdecken
CrossrefInfokarte

False‐Positive Hepatitis C Virus Serology Following HeartMate 3 Left Ventricular Assist Device Implantation

Chae Rin Im, Olly Allen, A. Ruth M. Kappeler, Sumita Pai, Jo Pocock, Sai Bhagra, Marius Berman, Paul Lincoln, Chris Smith, Stephen Pettit

Artificial Organs · 2026-11-09

DOI: 10.1111/aor.70282 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background False‐positive hepatitis C virus (HCV) (FPHC) serology has been reported with earlier‐generation axial‐flow left ventricular assist devices (LVADs), but its frequency with the magnetically levitated HeartMate 3 and its implications for heart transplant pathways remain unknown. This study describes FPHC serology in HeartMate 3 LVAD recipients and explores associated clinical and immunological features. Methods A retrospective, single‐center study was conducted at a specialist cardiothoracic center. All adults implanted with a HeartMate 3 LVAD between March 2018 and July 2025 with complete HCV serology before and after implantation were included. Patients developing HCV antibody positivity with negative confirmatory testing were classified as having FPHC serology. Patient demographics, blood product transfusions, liver function tests, lactate dehydrogenase, and human leukocyte antigen (HLA) sensitization were compared between groups. Results Among 54 HeartMate 3 LVAD recipients, 10 (18.5%) developed FPHC serology after implantation. There were no significant differences between groups in age, sex, liver function tests, or lactate dehydrogenase. The number of fresh frozen plasma units transfused at implantation and the development of anti‐HLA Class I antibodies were associated with FPHC serology ( p = 0.039, p = 0.04, respectively). No significant associations were observed with red blood cell or platelet transfusions. Conclusion FPHC serology is a clinically important phenomenon in HeartMate 3 LVAD recipients. Clinicians and patients should be aware of this phenomenon to minimize unnecessary investigations and delays to transplant candidacy assessment. Standardized confirmatory testing protocols and multicenter studies are needed to clarify the underlying immune mechanisms and their impact on post‐transplant outcomes.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →